We’ve gone over exactly this scenario: GTBP saw a pull back last week but the current trend on the chart could be signaling new support. GTBP is still holding potential gains of more than 15% since we started to follow the company last month.
After the action GTBP saw in late July, we could now be starting to see the previous resistance level around $2 become a new support on the GTBP daily chart:
Keep in mind that for GTBP, there is far more going on with the company now, which could pose potential catalysts to look forward to. Mainly, the recent news that the company signed an agreement with a Major Pharmaceutical Company to study its drug candidate OXS-1550 in combination with a Multi-Billion Dollar Oncology Drug on the 19th of July means that we will hopefully see who this “Major Pharma Company” will be, sometime. Furthermore, GTBP has begun to once again add to its strong board.
Keep GTBP on your radar. And stay tuned for more.
Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC, Midam Ventures LLC and GT Biopharma, Midam has been paid $200,000 from the company and ZERO shares of GT Biopharma Inc. for a duration beginning July 16, 2018 and ending August 16, 2018. Midam Ventures has been paid an additional $200k by GT Biopharma and has extended its marketing period through Sept 16, 2018. We may buy or sell additional shares of (GTBP) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | email@example.com